Aemetis (NASDAQ:AMTX) Share Price Breaks Below Two Hundred Day Moving Average - Should You Sell?

Key Points

• Aemetis shares fell below their 200-day moving average, trading as low as $1.72 and last changing hands at $1.79, compared with the 200-day average of $2.15.
• Analyst sentiment remains mixed but centers on a “Hold” consensus: one analyst rates the stock Buy and another Sell, with a consensus price target of $11.88.
• Aemetis beat quarterly EPS expectations, reporting a $0.13 loss per share versus the expected $0.29 loss, but revenue of $62.7 million came in below the $67.69 million forecast.

Shares of Aemetis, Inc (NASDAQ:AMTX - Get Free Report) passed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $2.15 and traded as low as $1.72. Aemetis shares last traded at $1.79, with a volume of 577,930 shares.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Wall Street Zen upgraded Aemetis from a "sell" rating to a "hold" rating in a research note on Saturday, August 22nd. Weiss Ratings reiterated a "sell (e+)" rating on shares of Aemetis in a research note on Friday, July 17th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Aemetis currently has a consensus rating of "Hold" and a consensus price target of $11.88.

Aemetis Trading Up 1.1%

The company's 50-day moving average price is $1.79 and its two-hundred day moving average price is $2.15. The company has a market cap of $129.18 million, a P/E ratio of -1.97 and a beta of 1.47.

Aemetis (NASDAQ:AMTX - Get Free Report) last released its earnings results on Thursday, August 6th. The specialty chemicals company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.16. The business had revenue of $62.70 million for the quarter, compared to analyst estimates of $67.69 million. Equities analysts forecast that Aemetis, Inc will post -0.89 earnings per share for the current year.

Hedge Funds Weigh In On Aemetis

Hedge funds have recently modified their holdings of the stock. J. Derek Lewis & Associates Inc. purchased a new position in shares of Aemetis during the 4th quarter valued at $322,000. Bank of New York Mellon Corp purchased a new stake in shares of Aemetis during the second quarter worth $283,000. Renaissance Technologies LLC acquired a new stake in Aemetis during the first quarter valued at $272,000. Caitong International Asset Management Co. Ltd acquired a new stake in Aemetis during the fourth quarter valued at $115,000. Finally, Bank of America Corp DE grew its stake in Aemetis by 148.3% in the first quarter. Bank of America Corp DE now owns 101,486 shares of the specialty chemicals company's stock valued at $324,000 after purchasing an additional 60,611 shares in the last quarter. 27.02% of the stock is currently owned by institutional investors and hedge funds.

Aemetis Company Profile

Aemetis, Inc is a renewable fuels and biochemicals company focused on developing and operating technologies that reduce greenhouse gas emissions. Its activities include the production of renewable natural gas, renewable fuels, and other low-carbon products derived from agricultural and organic waste.

The company's Aemetis Biogas business develops and operates dairy-waste digesters and related infrastructure in California's Central Valley. These systems capture methane from dairy manure and convert it into renewable natural gas for transportation and other energy applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.